CN110573511B - 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途 - Google Patents

6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途 Download PDF

Info

Publication number
CN110573511B
CN110573511B CN201880027586.7A CN201880027586A CN110573511B CN 110573511 B CN110573511 B CN 110573511B CN 201880027586 A CN201880027586 A CN 201880027586A CN 110573511 B CN110573511 B CN 110573511B
Authority
CN
China
Prior art keywords
pyridin
pyrido
pyrimidin
amine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880027586.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110573511A (zh
Inventor
D·本克
F·贝伦斯特恩
郝学士
T·霍夫曼
金其辉
A·拉科斯特
C·李
刘峻
Y·刘
J·K·麦鲍姆
T·莫
J·潘
X·屈
J·特霍兹
谢云峰
S·闫
邹叶芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN202210409770.6A priority Critical patent/CN114621222B/zh
Priority to CN202210409194.5A priority patent/CN114703144A/zh
Publication of CN110573511A publication Critical patent/CN110573511A/zh
Application granted granted Critical
Publication of CN110573511B publication Critical patent/CN110573511B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/27—Lung cells, respiratory tract cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880027586.7A 2017-04-28 2018-04-26 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途 Active CN110573511B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210409770.6A CN114621222B (zh) 2017-04-28 2018-04-26 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途
CN202210409194.5A CN114703144A (zh) 2017-04-28 2018-04-26 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762491484P 2017-04-28 2017-04-28
US201762491475P 2017-04-28 2017-04-28
US201762491526P 2017-04-28 2017-04-28
US201762491573P 2017-04-28 2017-04-28
US62/491,573 2017-04-28
US62/491,484 2017-04-28
US62/491,475 2017-04-28
US62/491,526 2017-04-28
US201862650232P 2018-03-29 2018-03-29
US62/650,232 2018-03-29
PCT/IB2018/052919 WO2018198077A2 (en) 2017-04-28 2018-04-26 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202210409194.5A Division CN114703144A (zh) 2017-04-28 2018-04-26 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途
CN202210409770.6A Division CN114621222B (zh) 2017-04-28 2018-04-26 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途

Publications (2)

Publication Number Publication Date
CN110573511A CN110573511A (zh) 2019-12-13
CN110573511B true CN110573511B (zh) 2023-04-25

Family

ID=62148436

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880027586.7A Active CN110573511B (zh) 2017-04-28 2018-04-26 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途
CN202210409770.6A Active CN114621222B (zh) 2017-04-28 2018-04-26 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途
CN202210409194.5A Withdrawn CN114703144A (zh) 2017-04-28 2018-04-26 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210409770.6A Active CN114621222B (zh) 2017-04-28 2018-04-26 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途
CN202210409194.5A Withdrawn CN114703144A (zh) 2017-04-28 2018-04-26 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途

Country Status (25)

Country Link
US (2) US11458138B2 (cg-RX-API-DMAC7.html)
EP (1) EP3615537B1 (cg-RX-API-DMAC7.html)
JP (2) JP7247102B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190142776A (cg-RX-API-DMAC7.html)
CN (3) CN110573511B (cg-RX-API-DMAC7.html)
AU (2) AU2018260495B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019022512A2 (cg-RX-API-DMAC7.html)
CA (1) CA3056906A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003049A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019011873A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190483A (cg-RX-API-DMAC7.html)
CU (2) CU20200080A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2019000273A (cg-RX-API-DMAC7.html)
EC (1) ECSP19076732A (cg-RX-API-DMAC7.html)
ES (1) ES2983611T3 (cg-RX-API-DMAC7.html)
IL (2) IL269293B (cg-RX-API-DMAC7.html)
JO (1) JOP20190257A1 (cg-RX-API-DMAC7.html)
MA (1) MA49285A (cg-RX-API-DMAC7.html)
MX (1) MX2019012756A (cg-RX-API-DMAC7.html)
PE (1) PE20200292A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502436A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908615RA (cg-RX-API-DMAC7.html)
TW (1) TW201843140A (cg-RX-API-DMAC7.html)
UY (1) UY37703A (cg-RX-API-DMAC7.html)
WO (1) WO2018198077A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202109655VA (en) 2015-12-04 2021-10-28 Novartis Ag Compositions and methods for immunooncology
KR102558066B1 (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
IL273579B2 (en) 2017-09-27 2025-10-01 Incyte Corp Salts of pyrrolizidine derivatives used as Tm inhibitors.
TW202005643A (zh) 2018-06-08 2020-02-01 日商日產化學股份有限公司 激酶抑制劑
HRP20250676T1 (hr) 2018-06-29 2025-08-01 Incyte Corporation Formulacije inhibitora axl/mer
WO2020081673A1 (en) * 2018-10-16 2020-04-23 The Schepens Eye Research Institute, Inc. Bioadhesive for soft tissue repair
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
JP7395159B2 (ja) * 2018-12-11 2023-12-11 国立大学法人京都大学 ゲノムｄｎａに欠失を誘導する方法
WO2020158841A1 (ja) 2019-01-30 2020-08-06 日産化学株式会社 ヒドラジド化合物及びキナーゼ阻害剤
CN112707905B (zh) * 2019-10-25 2024-07-02 武汉誉祥医药科技有限公司 一种三并杂环化合物及其制备方法和用途
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
EP4065230A1 (en) * 2019-11-27 2022-10-05 Genentech, Inc. Therapeutic compounds
CA3170121A1 (en) * 2020-02-05 2021-08-12 The Rockefeller University Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss
CN111443068B (zh) * 2020-03-06 2023-06-27 天津大学 具有多重刺激响应特性的纯有机室温磷光材料及筛选方法和应用
CN115697343A (zh) 2020-03-06 2023-02-03 因赛特公司 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
WO2021220132A1 (en) 2020-04-27 2021-11-04 Novartis Ag Methods and compositions for ocular cell therapy
WO2021222363A1 (en) * 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Cycloalkyl pyrimidines as ferroportin inhibitors
CN112305126A (zh) * 2020-11-02 2021-02-02 宁夏贝利特生物科技有限公司 一种硝酸胍含量的测定方法
EP4392769A4 (en) * 2021-08-23 2025-07-09 Emd Millipore Corp SYSTEM AND METHOD FOR PHOTOPOLYMERIZATION OF ELECTROPHORETIC GELS
CN115974868B (zh) * 2022-11-07 2024-04-12 安徽理工大学 一种尿嘧啶衍生物的合成方法及其抗肺纤维化方面的潜在应用
WO2024211621A1 (en) * 2023-04-04 2024-10-10 Children's Hospital Los Angeles Lats kinase inhibitor to treat retinal degeneration
CN119462609B (zh) * 2024-10-25 2025-12-26 烟台皓元生物医药科技有限公司 一种lats抑制剂vt02956的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2733201A1 (en) * 2011-07-15 2014-05-21 Osaka University Method for preparing corneal endothelial cell
WO2015148597A1 (en) * 2014-03-25 2015-10-01 Ignyta, Inc. Azaquinazoline inhibitors of atypical protein kinase c

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065392A1 (en) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
AU2006217744A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited 2,4-diamino-pyridopyrimidine derivatives and their use as MTOR inhibitors
EA200901348A1 (ru) * 2007-04-06 2010-04-30 Новартис Аг Производные 2,6-нафтиридина, как модуляторы протеинкиназы
RU2473549C2 (ru) 2008-07-31 2013-01-27 Дженентек, Инк. Пиримидиновые соединения, композиции и способы применения
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
MX2014003612A (es) 2011-09-27 2014-07-09 Hoffmann La Roche Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso.
AU2013323360B2 (en) * 2012-09-28 2017-09-07 Cancer Research Technology Limited Azaquinazoline inhibitors of atypical protein kinase C
AU2014361781B2 (en) * 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
AR105575A1 (es) * 2015-08-03 2017-10-18 Bristol Myers Squibb Co COMPUESTOS DE QUINOLINA COMO MODULADORES DE TNFa
WO2017035116A1 (en) 2015-08-25 2017-03-02 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2733201A1 (en) * 2011-07-15 2014-05-21 Osaka University Method for preparing corneal endothelial cell
WO2015148597A1 (en) * 2014-03-25 2015-10-01 Ignyta, Inc. Azaquinazoline inhibitors of atypical protein kinase c

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Advances in corneal cell therapy;Matthias Fuest等;《Regenerative Medicine》;20160901;第601-615页 *
Comparison of culture media for ex vivo cultivation of limbal epithelial progenitor cells;Renata Ruoco loureiro;《Molecular Vision》;20130117;第69-77页 *
Concise Review: An Update on the Culture of Human Corneal Endothelial Cells for Transplantation;Mohit Parekh等;《STEM CELLS Translational Medicine》;20151223;第258-264页 *
Limbal Stem-Cell Therapy and Long-Term Corneal Regeneration;Paolo Rama等;《The New England Journal of Medicine》;20100708;第147-155页 *
Selective inhibition of ROCK kinase isoforms to promote neuroregeneration after brain surgery;Peng Wang等;《Medicinal Chemistry Research》;20150921;第40–50页 *
Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP;YaweiHao等;《 Journal of Biological Chemistry》;20080229;第5496-5509页 *

Also Published As

Publication number Publication date
JP7247102B2 (ja) 2023-03-28
RU2019138304A (ru) 2021-05-28
SG11201908615RA (en) 2019-11-28
UY37703A (es) 2018-11-30
AU2018260495A1 (en) 2019-10-17
AU2018260495B2 (en) 2021-09-16
JOP20190257A1 (ar) 2019-10-28
EP3615537B1 (en) 2024-03-06
CN110573511A (zh) 2019-12-13
CN114703144A (zh) 2022-07-05
CA3056906A1 (en) 2018-11-01
DOP2019000273A (es) 2019-12-15
US11458138B2 (en) 2022-10-04
US20230190751A1 (en) 2023-06-22
KR20190142776A (ko) 2019-12-27
BR112019022512A2 (pt) 2020-06-16
CN114621222A (zh) 2022-06-14
JP2020517698A (ja) 2020-06-18
ECSP19076732A (es) 2019-10-31
EP3615537A2 (en) 2020-03-04
WO2018198077A3 (en) 2019-02-14
WO2018198077A2 (en) 2018-11-01
CU20200080A7 (es) 2021-05-12
PE20200292A1 (es) 2020-02-05
MX2019012756A (es) 2019-12-16
CN114621222B (zh) 2024-12-17
AU2021286281A1 (en) 2022-01-06
MA49285A (fr) 2020-03-04
RU2019138304A3 (cg-RX-API-DMAC7.html) 2021-07-13
IL269293B (en) 2022-06-01
IL292857A (en) 2022-07-01
CL2019003049A1 (es) 2020-02-07
CU20190086A7 (es) 2020-11-30
JP2022188056A (ja) 2022-12-20
CR20190483A (es) 2019-11-20
US20180344738A1 (en) 2018-12-06
IL269293A (en) 2019-11-28
PH12019502436A1 (en) 2020-07-20
TW201843140A (zh) 2018-12-16
ES2983611T3 (es) 2024-10-23
CO2019011873A2 (es) 2020-01-17

Similar Documents

Publication Publication Date Title
CN110573511B (zh) 6-6稠合双环杂芳基化合物及其作为lats抑制剂的用途
US20200131474A1 (en) Methods and compositions for ocular cell therapy
US12312341B2 (en) Methods for treating cancer
JP2020517698A5 (cg-RX-API-DMAC7.html)
AU2016224975B2 (en) Small molecules that enable cartilage rejuvanation
US20230348852A1 (en) Methods and compositions for ocular cell therapy
CA2923765A1 (en) Stem cell modulation ii
RU2775721C2 (ru) 6-6-конденсированные бициклические гетероарильные соединения и их применение в качестве ингибиторов lats
US20250129067A1 (en) Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
EA038453B1 (ru) 6-6-конденсированные бициклические гетероарильные соединения и их применение в качестве ингибиторов lats
HK40055084A (en) Methods and compositions for ocular cell therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant